Obseva (NASDAQ:OBSV) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Saturday, Zacks.com reports. The firm presently has a $2.75 target price on the stock. Zacks Investment Research‘s target price indicates a potential upside of 11.79% from the stock’s current price.
According to Zacks, “ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman’s reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. “
Several other brokerages also recently commented on OBSV. HC Wainwright cut their target price on Obseva from $36.00 to $23.00 and set a “buy” rating on the stock in a report on Monday, October 5th. Wedbush reaffirmed a “buy” rating and set a $30.00 target price on shares of Obseva in a report on Friday, August 14th. BMO Capital Markets downgraded Obseva from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $5.00 to $4.00 in a research note on Monday, July 6th. JPMorgan Chase & Co. downgraded Obseva from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $18.00 to $5.00 in a research note on Tuesday, July 7th. Finally, SVB Leerink dropped their price objective on Obseva from $7.00 to $5.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $11.59.
Obseva (NASDAQ:OBSV) last announced its earnings results on Thursday, August 6th. The company reported ($0.38) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.04. Equities research analysts predict that Obseva will post -1.58 EPS for the current fiscal year.
Several large investors have recently made changes to their positions in the company. Logos Global Management LP acquired a new position in shares of Obseva in the 2nd quarter valued at about $6,862,000. California Public Employees Retirement System acquired a new position in Obseva during the 2nd quarter worth approximately $401,000. Aigen Investment Management LP acquired a new position in Obseva during the 2nd quarter worth approximately $212,000. Cutter & CO Brokerage Inc. acquired a new position in Obseva during the 2nd quarter worth approximately $193,000. Finally, Virtu Financial LLC acquired a new position in Obseva during the 2nd quarter worth approximately $279,000. 48.54% of the stock is currently owned by institutional investors.
Obseva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Recommended Story: Day Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.